Literature DB >> 10751546

Role of glutathione in the biliary excretion of the arsenical drugs trimelarsan and melarsoprol.

Z Gregus1, A Gyurasics.   

Abstract

After administration of the inorganic sodium arsenite or arsenate to rats, the biliary excretion of arsenic is rapid, is accompanied by the biliary output of large amounts of GSH, and is completely arrested by the GSH depletor diethyl maleate (DEM). We studied the biliary excretion of trimelarsan (TMA) and melarsoprol (MAP) in rats in order to determine whether biliary excretion is also significant in the disposition of these trivalent organic arsenicals that are used as therapeutic agents and whether GSH is also involved in their hepatobiliary transport. After injection of either drug (100 micromol/kg, i.v.), arsenic was rapidly excreted in bile (up to 1 micromol/kg. min, approximately 55% of dose/100 min). Concurrently, TMA and MAP increased the biliary output of GSH 3- and 6 fold, and lowered the hepatic GSH content by 24% and 27%, respectively. In TMA-injected rats, pretreatment with DEM or buthionine sulfoximine decreased the initial biliary excretion of arsenic by 75% and 40%, respectively, whereas in MAP-injected rats these GSH depletors diminished arsenic output by 45% and 20%. Both arsenicals reacted with GSH in vitro, giving rise to the same product, which was also shown by HPLC analysis to be a major biliary metabolite of both TMA and MAP. This metabolite was sensitive to gamma-glutamyltranspeptidase in vitro and its biliary excretion was virtually prevented by the GSH depletors, confirming that it is a GSH conjugate (purportedly melarsen-diglutathione). Some TMA was excreted in the bile unchanged, whereas a significant amount of MAP also appeared there as two glucuronides. The biliary excretion of unchanged TMA and MAP glucuronides was increased by experimental depletion of GSH. These studies indicate that the biliary excretion of TMA and MAP (1) is very significant in their disposition, (2) is partially dependent on the hepatic availability of GSH, as these arsenicals are excreted in part as a GSH conjugate, and (3) is concomitant with the increased appearance of GSH in bile, probably originating from dissociation of the unstable GSH conjugate of these arsenicals. Thus, conjugation with GSH is important in the elimination of both TMA and MAP, although glucuronidation is also involved in the fate of MAP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10751546     DOI: 10.1016/s0006-2952(00)00263-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Speciation of arsenic in urine following intravenous administration of arsthinol in mice.

Authors:  Imane Ajana; Alain Astier; Stéphane Gibaud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-09       Impact factor: 2.441

2.  The MRP1-mediated effluxes of arsenic and antimony do not require arsenic-glutathione and antimony-glutathione complex formation.

Authors:  Milena Salerno; Maria Petroutsa; Arlette Garnier-Suillerot
Journal:  J Bioenerg Biomembr       Date:  2002-04       Impact factor: 2.945

3.  Toxicokinetic and genomic analysis of chronic arsenic exposure in multidrug-resistance mdr1a/1b(-/-) double knockout mice.

Authors:  Yaxiong Xie; Jie Liu; Yaping Liu; Curtis D Klaassen; Michael P Waalkes
Journal:  Mol Cell Biochem       Date:  2004-01       Impact factor: 3.396

4.  NRF2 Is a Potential Modulator of Hyperresistance to Arsenic Toxicity in Stem-Like Keratinocytes.

Authors:  Xiafang Wu; Bei Yang; Yuxin Hu; Ru Sun; Huihui Wang; Jingqi Fu; Yongyong Hou; Jingbo Pi; Yuanyuan Xu
Journal:  Oxid Med Cell Longev       Date:  2017-09-10       Impact factor: 6.543

5.  A case-control study of GST polymorphisms and arsenic related skin lesions.

Authors:  Kathleen M McCarty; Louise Ryan; E Andres Houseman; Paige L Williams; David P Miller; Quazi Quamruzzaman; Mahmuder Rahman; Golam Mahiuddin; Thomas Smith; Ernesto Gonzalez; Li Su; David C Christiani
Journal:  Environ Health       Date:  2007-02-06       Impact factor: 5.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.